Actively Recruiting
International Study on Long-Term Safety and Effectiveness of Sirolimus and Everolimus for Lymphangioleiomyomatosis in Adults
Led by University of Cincinnati · Updated on 2024-12-24
600
Participants Needed
20
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Lymphangioleiomyomatosis LAM is a rare lung disease that mainly affects women and causes lung cysts and progressive breathing problems. Researchers are studying the long-term safety and effects of mTOR inhibitors, specifically sirolimus and everolimus, in treating LAM. This observational study aims to follow patients who are currently using, have previously stopped, or may start these treatments as part of their medical care. The study is conducted by the University of Cincinnati and supported by the NIH Rare Lung Disease Consortium. Participants include women and men aged 18 or older with LAM, who are on chronic mTOR inhibitor therapy, newly treated, or may be considered for treatment. The study tracks patients receiving sirolimus or everolimus as prescribed by their doctors, without assigning treatments. It observes real-world use of these drugs over several years, focusing on safety and lung function. During the study, researchers will collect lung function tests and monitor adverse events for at least 2 years, with some outcomes followed up to 5 years. Patients will be seen at least once per year at a Rare Lung Disease Clinic, and pulmonary function testing will be performed. The main outcomes measured are the safety of long-term mTOR inhibitor use and changes in lung function, including forced expiratory volume FEV1. Quality of life will also be evaluated. Participation requires informed consent and willingness to attend clinic visits and perform lung tests.
CONDITIONS
Brief Title
Safety and Durability of Sirolimus for Treatment of LAM
Research Team
S
Susan McMahan Sellers, BSN, RN
F
Francis X McCormack, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here